Benzinga's Top Downgrades By: Benzinga via Benzinga December 04, 2014 at 09:16 AM EST Analysts at Credit Suisse downgraded BIND Therapeutics (NASDAQ: BIND) from Outperform to Neutral. The price target for BIND Therapeutics ... Read More >> Related Stocks: Circor International Kindred Biosciences Thor Industries